Monthly information on share capital and company voting rights

Rhea-AI Summary

Cellectis, a clinical-stage biotechnology company, announced key information regarding its share structure as of March 31, 2023. The total number of shares in capital stands at 55,583,768, while the total number of voting rights is 61,504,923. Cellectis focuses on innovative gene editing technologies, specifically TALEN and PulseAgile, to develop advanced cell and gene therapies aimed at treating cancers such as acute myeloid leukemia and multiple myeloma. The company operates under two primary platforms: UCART for CAR-T immunotherapies and .HEAL for hemopoietic stem cell therapies. Cellectis is listed on Nasdaq (CLLS) and Euronext Growth (ALCLS), with headquarters in Paris and additional locations in New York and Raleigh.

Positive

• Total number of voting rights increased to 61,504,923, indicating strong shareholder interest.
• Cellectis is advancing in gene editing technology, which can enhance its market position.
• The company is dedicated to developing therapies for unmet medical needs, particularly in oncology.

Negative

• None.

(Article 223-16 of General Regulation of the French financial markets authority)

NEW YORK, April 12, 2023 (GLOBE NEWSWIRE) --

Listing market: Euronext Growth

ISIN code: FR0010425595

Date	Total number of shares in the capital	Total number of voting rights
03/31/2023	55,583,768	61,504,923

About Cellectis
Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. Cellectis utilizes an allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to make therapeutic gene editing in hemopoietic stem cells for various diseases. As a clinical-stage biopharmaceutical company with over 23 years of expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN®, its gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to treat diseases with unmet medical needs. As part of its commitment to a cure, Cellectis remains dedicated to its goal of providing lifesaving UCART product candidates for multiple cancers including acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL) and multiple myeloma (MM). .HEAL is a new platform focusing on hemopoietic stem cells to treat blood disorders, immunodeficiencies and lysosomal storage diseases.

Cellectis’ headquarters are in Paris, France, with locations in New York, New York and Raleigh, North Carolina.

Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS).

For more information, visit www.cellectis.com
Follow Cellectis on social media: @cellectis, LinkedIn and YouTube.

For further information, please contact:

Media contact:
Pascalyne Wilson, Director, Communications, +33776991433, media@cellectis.com

Investor Relation contacts:
Arthur Stril, Chief Business Officer, +1 (347) 809 5980, investors@cellectis.com
Ashley R. Robinson, LifeSci Advisors, +1 (617) 430 7577

Attachment

• Voting_Rights_PR_March 2023_EN_docx

FAQ

What are the total shares and voting rights for Cellectis as of March 2023?

As of March 31, 2023, Cellectis has a total of 55,583,768 shares in capital and 61,504,923 voting rights.

What is Cellectis' focus in biotechnology?

Cellectis specializes in gene editing technologies to develop therapies for cancer and blood disorders, particularly using TALEN and PulseAgile.

On which stock exchanges is Cellectis listed?

Cellectis is listed on the Nasdaq Global Market under the ticker CLLS and on Euronext Growth under the ticker ALCLS.

What types of cancers does Cellectis aim to treat?

Cellectis focuses on treating acute myeloid leukemia, B-cell acute lymphoblastic leukemia, and multiple myeloma.